ELABRETH Trademark

Trademark Overview

On Thursday, November 20, 2014, a trademark application was filed for ELABRETH with the United States Patent and Trademark Office. The USPTO has given the ELABRETH trademark a serial number of 86460425. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, January 20, 2020. This trademark is owned by Glaxo Group Limited. The ELABRETH trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Vaccines
elabreth

General Information

Serial Number86460425
Word MarkELABRETH
Filing DateThursday, November 20, 2014
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, January 20, 2020
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, October 25, 2016

Trademark Statements

Goods and ServicesPharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological, gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Vaccines
Translation of Words in MarkThe wording "ELABRETH" has no meaning in a foreign language.

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateSaturday, November 29, 2014
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameGlaxo Group Limited
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressBrentford, Middlesex TW89GS
Party NameGlaxo Group Limited
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressBrentford, Middlesex TW89GS

Trademark Events

Event DateEvent Description
Tuesday, January 21, 2020ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, January 20, 2020ABANDONMENT - NO USE STATEMENT FILED
Monday, December 9, 2019ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Monday, December 9, 2019TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Wednesday, June 19, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, June 18, 2019EXTENSION 5 GRANTED
Friday, June 14, 2019EXTENSION 5 FILED
Tuesday, June 18, 2019CASE ASSIGNED TO INTENT TO USE PARALEGAL
Friday, June 14, 2019TEAS EXTENSION RECEIVED
Wednesday, December 12, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, December 10, 2018EXTENSION 4 GRANTED
Monday, December 10, 2018EXTENSION 4 FILED
Monday, December 10, 2018TEAS EXTENSION RECEIVED
Friday, June 15, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, June 13, 2018EXTENSION 3 GRANTED
Wednesday, June 13, 2018EXTENSION 3 FILED
Wednesday, June 13, 2018TEAS EXTENSION RECEIVED
Tuesday, November 7, 2017NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Saturday, November 4, 2017EXTENSION 2 GRANTED
Saturday, November 4, 2017EXTENSION 2 FILED
Saturday, November 4, 2017TEAS EXTENSION RECEIVED
Thursday, June 15, 2017NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, June 13, 2017EXTENSION 1 GRANTED
Tuesday, June 13, 2017EXTENSION 1 FILED
Tuesday, June 13, 2017TEAS EXTENSION RECEIVED
Tuesday, December 20, 2016NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, October 25, 2016OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, October 25, 2016PUBLISHED FOR OPPOSITION
Wednesday, October 5, 2016NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Friday, September 16, 2016APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, March 16, 2016NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Wednesday, March 16, 2016LETTER OF SUSPENSION E-MAILED
Wednesday, March 16, 2016SUSPENSION LETTER WRITTEN
Wednesday, September 16, 2015NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Wednesday, September 16, 2015INQUIRY TO SUSPENSION E-MAILED
Wednesday, September 16, 2015SUSPENSION INQUIRY WRITTEN
Tuesday, June 23, 2015TEAS CHANGE OF CORRESPONDENCE RECEIVED
Monday, March 16, 2015NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Monday, March 16, 2015LETTER OF SUSPENSION E-MAILED
Monday, March 16, 2015SUSPENSION LETTER WRITTEN
Tuesday, March 10, 2015ASSIGNED TO EXAMINER
Saturday, November 29, 2014NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Monday, November 24, 2014NEW APPLICATION ENTERED IN TRAM

Related Keywords

elabreth pharmaceutical treatment disorders preparations substances diseases ophthalmic respiratory hepatological oncological